Faron Pharmaceuticals Doses First Patient in BLAZE Phase 1/2 Trial
Faron Pharmaceuticals has dosed the first patient in the BLAZE trial, testing bexmarilimab combined with nivolumab for patients with anti-PD-1-resistant NSCLC and melanoma.
Faron Pharmaceuticals has dosed the first patient in the BLAZE trial, testing bexmarilimab combined with nivolumab for patients with anti-PD-1-resistant NSCLC and melanoma.